0000914475-24-000100.txt : 20240403 0000914475-24-000100.hdr.sgml : 20240403 20240403164407 ACCESSION NUMBER: 0000914475-24-000100 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Delaet Ingrid CENTRAL INDEX KEY: 0001965808 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24819580 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1712177026.xml FORM 4 X0508 4 2024-04-01 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001965808 Delaet Ingrid 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer 1 Common Stock 2024-04-01 4 M 0 272 79.02 A 7779 D Common Stock 2024-04-01 4 S 0 272 137.30 D 7507 D Non-Qualified Stock Option 79.02 2024-04-01 4 M 0 272 79.02 D 2032-01-31 Common Stock 272 5172 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. /s/ Darin Lippoldt, Attorney-in-Fact 2024-04-03